Dosage and administration of Dacomitinib in Laos and its use in special populations
Dacomitinib is a targeted therapy drug mainly used for specific types of non-small cell lung cancer. Its usage and dosage need to be adjusted according to the patient's situation, and special attention should be paid to medication for special populations. The following provides detailed instructions on usage, dosage, and medication for special populations.
1. Usage and dosage
(1) Conventional dosage
The recommended dose of Dakatinib is 45 milligrams orally once daily, which can be taken with food or on an empty stomach. Continue treatment until disease progression or unacceptable toxicity occurs.
(2) Dose adjustment
If serious adverse reactions occur, consider reducing to 30 milligrams or 15 milligrams per day. The specific adjustment plan needs to be based on the patient's tolerance and the doctor's advice.
2. Medication for special populations
(1) Pregnancy period
Dakatinib may cause harm to the fetus, and pregnant women and women with reproductive potential need to use effective contraceptive measures. Pregnancy should be avoided during treatment and for at least 17 days after discontinuation of medication.
(2) Lactation period
It is not yet clear whether Dakatinib is secreted through breast milk. It is recommended that lactating women avoid breastfeeding during the medication period and for 17 days after discontinuation to reduce the risk of infant exposure.
(3) Elderly patients
The safety and efficacy of patients aged 65 and above are not significantly different from those of younger patients, but adverse reactions need to be closely monitored as they may be more prone to certain side effects.
(4) Liver dysfunction
Patients with mild to moderate liver dysfunction do not need to adjust the dosage, while patients with severe liver dysfunction should use it with caution and reduce the dosage under the guidance of a doctor if necessary.
(5) Renal insufficiency
Patients with mild to moderate renal insufficiency do not need to adjust the dosage, and there is limited data on the use of medication in patients with severe renal insufficiency, so the risk benefit ratio needs to be carefully evaluated.
(6) Pediatric patients
The safety and efficacy of Dakatinib in patients under 18 years old have not been established, and it is not recommended for use in children and adolescents.
Disclaimer：《Dosage and administration of Dacomitinib in Laos and its use in special populations》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！